Home >> Top News >> Agena, PerkinElmer team up

Agena, PerkinElmer team up

Print Friendly, PDF & Email

Aug. 24, 2018—Agena Bioscience announced it has entered into a collaboration with PerkinElmer, incorporating the LabChip GX Touch nucleic acid analyzer for quality assessment and quantitation of DNA in the upfront workflow of Agena’s MassArray system. The companies have focused on targeting ctDNA in oncology liquid biopsy, where the combined systems aim to support a low cost, highly robust, single-day sample-to-results workflow for laboratories.

PerkinElmer’s LabChip GX Touch nucleic acid analyzer provides electrophoretic visual quality assessment and quantitation down to 25 pg/µL for DNA in as few as 30 seconds with flexible sample throughput options, including 96-well and 384-well. This provides a streamlined upfront process to Agena’s 96- and 384-chip systems and the UltraSeek chemistry for liquid biopsy.

Agena reported that in evaluations performed by its scientific affairs team, the LabChip system “ensured that sufficient DNA was present in the sample to achieve the sensitivity capabilities of the UltraSeek chemistry while efficiently identifying samples compromised by preanalytical variables that could result in false-negative results.”

“Controlling preanalytical variables is an important component of delivering robust reproducible liquid biopsy analysis. The combination of LabChip GX Touch nucleic acid analyzer’s sample qualification with UltraSeek assay’s highly sensitive, multiplexed chemistry delivers a powerful liquid biopsy sample-to-result solution,” Darryl Irwin, senior director of scientific affairs at Agena, said in a press release.

x

Check Also

Assessment of somatic mutations in pulmonary NSCLC with MassArray, 12/17

December 2017—Agena Bioscience announced a comparative study published in PLOS One (Sutton BC, et al. 2017;12[9]:e0183715) highlighting the use of its mass-spectrometry-based platform and iPlex HS chemistry for detection of somatic mutations in EGFR, KRAS, BRAF, and NRAS occurring in non-small cell lung cancer.

X